Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LGG-IL15-PSA
- Development stage
- Preclinical
- Lead developer
- National University of Singapore
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intravesical
01
Overview
**LGG-IL15-PSA** is a preclinical, genetically engineered *Lactobacillus rhamnosus* GG live biotherapeutic designed for cancer immunotherapy. The recombinant bacterium secretes a murine interleukin-15 and human prostate-specific antigen fusion construct, aiming to promote dendritic-cell maturation, T-cell proliferation, and prostate-specific antigen-directed cytotoxic T-lymphocyte activity against prostate-specific antigen-expressing tumor cells. In a murine orthotopic bladder-cancer model using MB49-PSA cells, intravesical administration was investigated as an alternative to BCG and was reported to induce tumor immune-cell infiltration and tumor cures in mice.
02
Targets
IL2RG (Interleukin-2 receptor gamma subunit)IL15RA (Interleukin-15 receptor subunit alpha)IL2RB (IL-2 receptor beta chain)PSA/pMHC (Kallikrein-3 (PSA) and PSA-derived peptide-MHC complexes)
Beyond the preview
Go deeper on LGG-IL15-PSA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LGG-IL15-PSA.